1. ODYSSEY LONG TERM
Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab 150 mg SQ injection every 2 weeks (n = 1,553) vs. placebo SQ injection every 2 weeks (n = 788).
(p < )
Results
From baseline to 24 weeks, the change in LDL-C: -61% for alirocumab compared with 0.8% for placebo (p < )
This reduction was maintained to 52 weeks; LDL-C: 53 mg/dl with alirocumab vs. 123 mg/dl with placebo
Percent change in LDL-C from baseline to 24 weeks
0.8 %
Conclusions
Among participants with heterozygous familial hypercholesterolemia or high CV risk, alirocumab resulted in a large reduction in LDL-C compared with placebo, which was maintained to 52 weeks
-61
Alirocumab
Placebo
Presented by Dr. Jennifer Robinson at ESC 2014